HDAC6 Inhibitor Patent, Inventors Vankayalapati et al
Summary
The USPTO has published patent application US20260109690A1, filed on May 30, 2025, covering HDAC6 inhibitor compounds having Structure (I) and their methods of use for therapeutic applications. The application names Hariprasad Vankayalapati, Zhaoliang Li, Chenyu Lin, Kyle Medley, and David J. Bearss as inventors. CPC classifications span multiple heterocyclic compound categories including C07D 413/12, A61K 31/506, A61P 21/00, and A61P 25/28, indicating potential neuromuscular and neurological applications.
“Compounds having activity as inhibitors of HDAC6 are provided.”
About this source
GovPing monitors USPTO Patent Applications - Therapeutics (A61P) for new healthcare & life sciences regulatory changes. Every update since tracking began is archived, classified, and available as free RSS or email alerts — 226 changes logged to date.
What changed
The USPTO published patent application US20260109690A1, a new application for HDAC6 (Histone Deacetylase 6) inhibitor compounds and associated therapeutic methods. The application covers compounds of Structure (I), including their pharmaceutical salts, stereoisomers, and tautomers, along with methods to prepare and use them and pharmaceutical compositions comprising such compounds.
Affected parties including pharmaceutical manufacturers, biotech firms, and researchers working in HDAC6 inhibition should monitor this application for potential freedom-to-operate implications. The CPC classifications (A61P 21/00, A61P 25/28) suggest neuromuscular and central nervous system therapeutic targets, which may overlap with existing drug development programs in these areas.
Archived snapshot
Apr 24, 2026GovPing captured this document from the original source. If the source has since changed or been removed, this is the text as it existed at that time.
HDAC6 INHIBITORS AND METHOD OF THEIR USE
Application US20260109690A1 Kind: A1 Apr 23, 2026
Inventors
Hariprasad Vankayalapati, Zhaoliang Li, Chenyu Lin, Kyle Medley, David J. Bearss
Abstract
Compounds having activity as inhibitors of HDAC6 are provided. The compounds have Structure (I): or a pharmaceutically acceptable salt, stereoisomer, or tautomer thereof, wherein X, R1, R2, R3, and Rb are as defined herein. Methods associated with preparation and use of such compounds, pharmaceutical compositions comprising such compounds and methods to modulate the activity of HDAC6 are also provided.
CPC Classifications
C07D 413/12 A61K 31/506 A61K 31/5377 A61K 31/5386 A61P 21/00 A61P 25/28 C07D 401/04 C07D 401/12 C07D 403/12 C07D 405/14 C07D 413/04 C07D 413/14 C07D 491/107 C07D 498/08 C07D 498/10
Filing Date
2025-05-30
Application No.
19223811
Mentioned entities
Related changes
Get daily alerts for USPTO Patent Applications - Therapeutics (A61P)
Daily digest delivered to your inbox.
Free. Unsubscribe anytime.
Source
About this page
Every important government, regulator, and court update from around the world. One place. Real-time. Free. Our mission
Source document text, dates, docket IDs, and authority are extracted directly from USPTO.
The summary, classification, recommended actions, deadlines, and penalty information are AI-generated from the original text and may contain errors. Always verify against the source document.
Classification
Who this affects
Taxonomy
Browse Categories
Get alerts for this source
We'll email you when USPTO Patent Applications - Therapeutics (A61P) publishes new changes.
Subscribed!
Optional. Filters your digest to exactly the updates that matter to you.